Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

Nkarta (NKTX) will host a webcast on November 9, 2026, to discuss initial NKX019 clinical data in autoimmune diseases.

Rhea-AI Summary

Nkarta (NKTX) will host a webcast on November 9, 2026, to discuss initial NKX019 clinical data in autoimmune diseases. The webcast begins at 8:00 a.m. ET and will review Ntrust program data in myositis and systemic sclerosis being presented at American College of Rheumatology Convergence 2026 in Orlando. A replay will be archived in the Investors section of Nkarta’s website.

Argus 15 min delay 47 alerts

+8.09% vs previous close $1.87 last price 1.2x rel. volume Open Argus

Details

Market move: NKTX +8.09% vs previous close. NKX019 clinical data webcast

+14.5% Peak in 5 min

$1.60 – $1.89 Day Range

$133.94M Mkt Cap at Last Price

On Nov 6, the day this news came out, the latest delayed price for NKTX is 8.09% above the previous close. Argus tracked a peak move of +14.5% during the session. Our momentum scanner has recorded 47 alerts for this stock so far that day. The latest delayed price is $1.87.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Webcast time: November 9, 2026, 8:00 a.m. ET

Webcast time

November 9, 2026, 8:00 a.m. ET

Scheduled review of initial NKX019 clinical data

Key Terms

open-label, dose-escalation, lymphodepletion, chimeric antigen receptor, +1 more

5 terms

open-label medical

"multi-center, open-label, dose-escalation clinical trials"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

dose-escalation medical

"multi-center, open-label, dose-escalation clinical trials"

Dose-escalation is the part of an early-stage clinical trial where researchers gradually increase a drug’s dose in small groups of participants to find the safest and most effective amount. Think of it like turning up the volume slowly to find the sweet spot: investors watch these results closely because they reveal safety risks, potential effectiveness, and how quickly a drug can move to later trials or approval, all of which affect the development timeline and commercial prospects.

lymphodepletion medical

"receiving lymphodepletion followed by CD19-targeted CAR-NK cell therapy"

Lymphodepletion is a short medical treatment that lowers a patient’s lymphocytes, the immune cells that can interfere with certain cell-based therapies, to create a more supportive environment for the new therapy to work. Think of it like clearing a crowded garden bed before planting seeds: by temporarily reducing competing cells, the engineered therapy can take hold more effectively. Investors watch lymphodepletion because it affects clinical trial results, safety profiles, treatment adoption, and overall commercial potential.

chimeric antigen receptor medical

"engineered with a humanized CD19-directed chimeric antigen receptor (CAR)"

A chimeric antigen receptor is an engineered protein added to a patient’s immune cells that gives them a new, specific ability to recognize and attack cells carrying a particular marker (antigen) — like equipping police with a facial‑recognition app to find a suspect. For investors, CARs are the core technology behind targeted cell therapies: their clinical success, manufacturing complexity, safety profile, and regulatory approval determine treatment market potential, development costs, and company value.

interleukin-15 medical

"a proprietary, membrane-bound form of interleukin-15 (IL-15)"

Interleukin-15 is a small immune signaling protein that helps activate and grow certain white blood cells, especially natural killer cells and T cells, which hunt infections and abnormal cells. Investors watch it because drugs or vaccines that boost, mimic, or block this signal can power new therapies for cancer, infectious disease, or immune disorders; think of it as a coach that can sharpen the immune team, so successful programs can drive substantial clinical and commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. ET, to review initial clinical data from its Ntrust program evaluating NKX019 in myositis and systemic sclerosis being presented at the American College of Rheumatology (ACR) Convergence 2026 in Orlando.

Live Webcast
To access the webcast, please register through this link: https://nkarta-clinical-update-acr-convergence-2026.open-exchange.net/

A replay will be archived on the Investors section of Nkarta’s website, www.nkartatx.com.

About the Ntrust℠ Clinical Trials in Autoimmune Disease
Ntrust-1 (NCT06557265) and Ntrust-2 (NCT06733935) are multi-center, open-label, dose-escalation clinical trials in patients with autoimmune disease receiving lymphodepletion followed by CD19-targeted CAR-NK cell therapy. Both trials assess the safety of NKX019 in people living with autoimmune diseases as well as its potential to achieve durable remission via a “reset” of the immune system through the elimination of pathogenic B cells.  

The Ntrust trials are enrolling up to 12 patients per dose level per disease indication, with leading indications in myositis and systemic sclerosis, as well as ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis, and primary membranous nephropathy. Additional patients may be enrolled if needed to refine patient populations for further study.

In both studies, patients receive a three-dose cycle of NKX019 following lymphodepletion with fludarabine and cyclophosphamide or cyclophosphamide alone, if they have significant cytopenia at baseline. This approach is designed to evaluate the single-agent activity of NKX019 and facilitate a more rapid path to regulatory approval. Patients in both trials may also receive additional cycles, if needed, to restore response or enable a deeper response.
   
About NKX019
NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed chimeric antigen receptor (CAR) for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease. Nkarta is evaluating NKX019 in multiple autoimmune conditions.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enable a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com